APRE Aprea Therapeutics, Inc.
$0.77▼ -1.94%
Healthcare
Other
After hours
$0.77▼ -0.50%
Sep 11, 7:12 PM ET
Volume 126.5K
Avg Volume (10D) 334.8K
Key Metrics & Fundamentals
Market Cap
$9.74M
P/E Ratio
–
Div Yield
–%
52W Range
0.55 - 1.69
% vs 50 MA
8.04%
% vs 200 MA
-4.60%
RSI-14
50.8
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.90
Free Cash Flow
-$3.29M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.03M
COGS
–
Operating Exp
$4.03M
Operating Income
-$4.03M
EBIT
-$4.03M
Pretax Income
-$3.59M
Net Income
-$3.59M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 10, 2026 12:00 PM
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
GlobeNewswire · Aug 28, 2026 12:15 PM
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
GlobeNewswire · Aug 12, 2026 12:30 PM
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 6, 2026 11:10 PM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 4, 2026 12:25 PM
Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026
GlobeNewswire · Jul 30, 2026 12:00 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See APRE's money flow as a full page
Social Sentiment
No Reddit posts found for APRE.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.